2018
Jeff Aronin is Named Innovator of the Year by Best in Biz
With its highest honor, a Gold level award, Best in Biz recognizes Jeff Aronin for his lifelong commitment to developing breakthrough therapies for severe medical [...]
Paragon Biosciences Announces $71.8 Million in New Investment for Portfolio Company Castle Creek Pharma
Paragon organizes new investment from Fidelity Management & Research Company and Valor Equity Partners for portfolio company Castle Creek Pharma CHICAGO, IL – October [...]
Crain’s Chicago Business: “Chicago-based Biotech Incubator Raises $71.8 Million”
October 19, 2019 – Paragon Biosciences CEO Jeff Aronin spoke with Crain’s Chicago Business on his role in the company, his vision for Paragon, and his [...]
Jeff Aronin Named One of the 20 Most Influential Leaders in Healthcare for 2018
Paragon CEO Jeff Aronin Recognized by Insights Care Magazine as “Innovative Entrepreneur Putting Patients First” October 1, 2018 – Paragon Biosciences CEO Jeff Aronin was [...]
Paragon Biosciences Announces Skyline Biosciences as the Newest Addition to Its Growing Portfolio of Companies
CHICAGO – August 21, 2018 – Paragon Biosciences (Paragon) today announced Skyline Biosciences (Skyline) as the newest addition to its growing portfolio of drug-development companies. [...]
Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome
CHICAGO – August 14, 2018 – Biopharmaceutical company Emalex Biosciences (Emalex), the newest member of the Paragon Biosciences (Paragon) portfolio of companies, today announced it [...]
